Valneva stock breaks below its €2.49 support level and posts -44% over one year

A €2.49 support abandoned, far from the three moving averages

The stock falls 3.33% to €2.44 and drops below its €2.49 support level, a threshold the price had been defending for several sessions. It is significantly below its 20-day MA (€2.63, or 7.41% gap) and its 200-day MA (€3.02), following a 13% decline over one month. Among the largest declines in the SBF 120, it is tracking an index down 1.32% this Monday, in a Paris market affected by tensions over French debt, with the 10-year OAT at 4.79% according to the latest Bank of France reading from October 16.

This session follows a turbulent period for the stock. On October 7, the revocation of Ixchiq authorization in the United Kingdom caused the stock to decline, before partial rebounds on October 9 and 12. Valneva remains listed on two exchanges only: the ordinary share in Paris and the ADR on Nasdaq, very lightly traded, at a ratio of two shares per ADR.

A decision on the Lyme vaccine vaccine expected within the next twelve months

On October 14, Valneva announced its participation in several conferences dedicated to health, between Paris, Boston, New York and London, to present its value creation drivers. Foremost is its candidate vaccine against Lyme disease, for which regulatory decisions are expected within the next twelve months, according to first-half 2026 results published on August 12, 2026. During this publication, the laboratory had confirmed its 2026 outlook despite the persistent negative impact of geopolitical context on travel.

Among the cited risks was the dependency on IXIARO deliveries to the U.S. Department of Defense, with an uncertain timeline. The stock displays an RSI of 43.8 and a decline of nearly 44% over one year.